Physiomics Plc
Physiomics Plc provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the United States, and the European Union Switzerland. The company offers modeling, simulation, and data analysis services covering various ranges of oncology research and development using its proprietary Virtual Tumour pred… Read more
Physiomics Plc (PYC) - Net Assets
Latest net assets as of December 2025: GBX393.00K GBX
Based on the latest financial reports, Physiomics Plc (PYC) has net assets worth GBX393.00K GBX as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX558.00K) and total liabilities (GBX165.00K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | GBX393.00K |
| % of Total Assets | 70.43% |
| Annual Growth Rate | 7.22% |
| 5-Year Change | -40.62% |
| 10-Year Change | 239.05% |
| Growth Volatility | 135.69 |
Physiomics Plc - Net Assets Trend (2001–2025)
This chart illustrates how Physiomics Plc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Physiomics Plc (2001–2025)
The table below shows the annual net assets of Physiomics Plc from 2001 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | GBX692.17K | +144.99% |
| 2024-06-30 | GBX282.53K | -46.87% |
| 2023-06-30 | GBX531.72K | -45.45% |
| 2022-06-30 | GBX974.81K | -16.38% |
| 2021-06-30 | GBX1.17 Million | -11.35% |
| 2020-06-30 | GBX1.31 Million | +116.31% |
| 2019-06-30 | GBX607.91K | -11.90% |
| 2018-06-30 | GBX690.03K | +110.21% |
| 2017-06-30 | GBX328.25K | +60.79% |
| 2016-06-30 | GBX204.15K | -37.30% |
| 2015-06-30 | GBX325.62K | +138.57% |
| 2014-06-30 | GBX136.49K | -46.65% |
| 2013-06-30 | GBX255.82K | -65.17% |
| 2012-06-30 | GBX734.57K | -2.83% |
| 2011-06-30 | GBX756.00K | -3.94% |
| 2010-06-30 | GBX787.00K | +1025.88% |
| 2009-06-30 | GBX-85.00K | +75.99% |
| 2008-06-30 | GBX-354.00K | -457.58% |
| 2007-06-30 | GBX99.00K | +250.00% |
| 2006-06-30 | GBX-66.00K | -115.98% |
| 2005-06-30 | GBX413.00K | +216.67% |
| 2004-06-30 | GBX-354.00K | -174.42% |
| 2003-06-30 | GBX-129.00K | -199.23% |
| 2001-06-30 | GBX130.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Physiomics Plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 767134200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | GBX1.21 Million | 175.22% |
| Other Comprehensive Income | GBX1.02 Million | 147.62% |
| Other Components | GBX6.27 Million | 905.97% |
| Total Equity | GBX692.17K | 100.00% |
Physiomics Plc Competitors by Market Cap
The table below lists competitors of Physiomics Plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Unicap Modaraba
KAR:UCAPM
|
$147.95 |
|
A.I.S. AG (LUM.SG)
STU:LUM
|
$148.40 |
|
Bankers Investment Trust
LSE:BNKR
|
$148.49 |
|
ADDvantage Technologies Group Inc
PINK:AEYGQ
|
$148.54 |
|
Crescent Star Insurance Ltd
KAR:CSIL
|
$147.39 |
|
Real Estate Credit Investments Limited
LSE:RECI
|
$146.87 |
|
AHLERS - Dusseldorf Stock Exchang
DU:AAH
|
$146.71 |
|
Unitronix Corporation
PINK:UTRX
|
$146.35 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Physiomics Plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 282,527 to 692,171, a change of 409,644 (145.0%).
- Net loss of 415,254 reduced equity.
- New share issuances of 906,417 increased equity.
- Other comprehensive income decreased equity by 23,002.
- Other factors decreased equity by 58,517.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | GBX-415.25K | -59.99% |
| Share Issuances | GBX906.42K | +130.95% |
| Other Comprehensive Income | GBX-23.00K | -3.32% |
| Other Changes | GBX-58.52K | -8.45% |
| Total Change | GBX- | 144.99% |
Book Value vs Market Value Analysis
This analysis compares Physiomics Plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 146.23x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 7.52x to 146.23x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2001-06-30 | GBX0.06 | GBX0.43 | x |
| 2003-06-30 | GBX-0.06 | GBX0.43 | x |
| 2004-06-30 | GBX-0.15 | GBX0.43 | x |
| 2005-06-30 | GBX0.18 | GBX0.43 | x |
| 2006-06-30 | GBX-0.03 | GBX0.43 | x |
| 2007-06-30 | GBX0.03 | GBX0.43 | x |
| 2008-06-30 | GBX-0.09 | GBX0.43 | x |
| 2009-06-30 | GBX-0.02 | GBX0.43 | x |
| 2010-06-30 | GBX0.09 | GBX0.43 | x |
| 2011-06-30 | GBX0.07 | GBX0.43 | x |
| 2012-06-30 | GBX0.06 | GBX0.43 | x |
| 2013-06-30 | GBX0.02 | GBX0.43 | x |
| 2014-06-30 | GBX0.01 | GBX0.43 | x |
| 2015-06-30 | GBX0.02 | GBX0.43 | x |
| 2016-06-30 | GBX0.01 | GBX0.43 | x |
| 2017-06-30 | GBX0.01 | GBX0.43 | x |
| 2018-06-30 | GBX0.01 | GBX0.43 | x |
| 2019-06-30 | GBX0.01 | GBX0.43 | x |
| 2020-06-30 | GBX0.02 | GBX0.43 | x |
| 2021-06-30 | GBX0.01 | GBX0.43 | x |
| 2022-06-30 | GBX0.01 | GBX0.43 | x |
| 2023-06-30 | GBX0.01 | GBX0.43 | x |
| 2024-06-30 | GBX0.00 | GBX0.43 | x |
| 2025-06-30 | GBX0.00 | GBX0.43 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Physiomics Plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -59.99%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -52.97%
- • Asset Turnover: 0.88x
- • Equity Multiplier: 1.29x
- Recent ROE (-59.99%) is above the historical average (-82.73%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2001 | -109.23% | 0.00% | 0.00x | 1.07x | GBX-155.00K |
| 2003 | 0.00% | -518.00% | 0.63x | 0.00x | GBX-246.10K |
| 2004 | 0.00% | -362.90% | 0.67x | 0.00x | GBX-189.60K |
| 2005 | -92.49% | -186.34% | 0.39x | 1.28x | GBX-423.30K |
| 2006 | 0.00% | -424.78% | 0.77x | 0.00x | GBX-473.40K |
| 2007 | -194.95% | -89.35% | 0.71x | 3.06x | GBX-202.90K |
| 2008 | 0.00% | -476.92% | 0.80x | 0.00x | GBX-398.63K |
| 2009 | 0.00% | 5.43% | 1.67x | 0.00x | GBX33.50K |
| 2010 | -46.76% | -240.52% | 0.17x | 1.17x | GBX-446.70K |
| 2011 | -85.32% | -1216.98% | 0.06x | 1.15x | GBX-720.60K |
| 2012 | -73.45% | -398.78% | 0.16x | 1.14x | GBX-613.03K |
| 2013 | -195.67% | -208.57% | 0.63x | 1.49x | GBX-526.15K |
| 2014 | -311.84% | -158.87% | 1.10x | 1.79x | GBX-439.27K |
| 2015 | -109.84% | -151.88% | 0.62x | 1.16x | GBX-390.22K |
| 2016 | -185.50% | -127.46% | 0.98x | 1.49x | GBX-399.11K |
| 2017 | -122.02% | -148.09% | 0.65x | 1.26x | GBX-433.35K |
| 2018 | -26.57% | -35.75% | 0.63x | 1.19x | GBX-252.34K |
| 2019 | -17.11% | -13.29% | 1.13x | 1.14x | GBX-164.83K |
| 2020 | -4.90% | -8.06% | 0.55x | 1.10x | GBX-195.92K |
| 2021 | -18.51% | -30.73% | 0.53x | 1.14x | GBX-332.40K |
| 2022 | -25.97% | -30.49% | 0.74x | 1.14x | GBX-350.62K |
| 2023 | -89.76% | -79.90% | 0.89x | 1.27x | GBX-530.43K |
| 2024 | -215.68% | -112.17% | 1.29x | 1.50x | GBX-637.60K |
| 2025 | -59.99% | -52.97% | 0.88x | 1.29x | GBX-484.47K |
Industry Comparison
This section compares Physiomics Plc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $10,807,025
- Average return on equity (ROE) among peers: -134.93%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Physiomics Plc (PYC) | GBX393.00K | -109.23% | 0.42x | $147.57 |
| 4BASEBIO UK SOCIETAS (4BB) | $11.70 Million | -27.66% | 0.26x | $10.53K |
| Aptamer Group PLC (APTA) | $8.05 Million | -26.00% | 0.43x | $3.12K |
| Arecor Therapeutics PLC (AREC) | $773.79K | -355.70% | 4.54x | $3.33K |
| Bioventix (BVXP) | $4.20 Million | 36.18% | 0.07x | $9.85K |
| Cizzle Biotechnology Holdings PLC (CIZ) | $741.00K | -0.02% | 3.16x | $747.56 |
| Fusion Antibodies PLC (FAB) | $1.46 Million | 79.21% | 0.28x | $2.07K |
| Faron Pharmaceuticals Oy (FARN) | $1.61 Million | -823.73% | 5.34x | $27.00K |
| Futura Medical (FUM) | $9.72 Million | -50.98% | 0.21x | $424.60 |
| hVIVO plc (HVO) | $2.86 Million | -195.31% | 2.17x | $5.18K |
| International Biotechnology Trust plc (IBT) | $66.95 Million | 14.71% | 0.00x | $997.94 |